Cyclodextrin multicomponent complexation and controlled release delivery strategies to optimize the oral bioavailability of vinpocetine.
In the present work, to maintain a suitable blood level of vinpocetine (VP) for a long period of time, VP-cyclodextrin-tartaric acid multicomponent complexes were prepared and formulated in hydroxypropylmethylcellulose matrix tablets. In vitro and in vivo performances of these formulations were investigated over a VP immediate release dosage form. Solubility studies were performed to evaluate the drug pH solubilization profile and to assess the effect of multicomponent complexation on VP solubility. The drug release process was investigated using United States Pharmacopeia apparatus 3 and a comparative oral pharmacokinetic study was subsequently undertaken in rabbits. Solubility studies denoted the pH-solubility dependence of VP and solubility improvement attained by complexation. Dissolution results showed controlled and almost complete release behavior of VP over a 12-h period from complex hydroxypropylmethylcellulose-based formulations. A clear difference between the pharmacokinetic patterns of VP immediate release and VP complex-based formulations was revealed. The area under the plasma concentration-time curve after oral administration of complex-based formulations was 2.1-2.9 times higher than that for VP immediate release formulation. Furthermore, significant differences found for mean residence time, elimination half-life, and elimination rate constant values corroborated prolonged release of VP from complex-based formulations. These results suggest that the oral bioavailability of VP was significantly improved by both multicomponent complexation and controlled release delivery strategies.
Ribeiro
Laura S S
LS
Laboratory of Pharmaceutical Tecnology, Faculty of Pharmacy, University of Coimbra, Rua do Norte, 3000-295 Coimbra, Portugal.
Falcão
Amílcar C
AC
Patrício
João A B
JA
Ferreira
Domingos C
DC
Veiga
Francisco J B
FJ
D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D004339:Drug Compounding; D006207:Half-Life; D006863:Hydrogen-Ion Concentration; D008657:Metabolic Clearance Rate; D008747:Methylcellulose / Q000031:analogs & derivatives / Q000737:chemistry; D008970:Molecular Weight; D011817:Rabbits; D015203:Reproducibility of Results; D012995:Solubility; D013607:Tablets; D013644:Tartrates / Q000737:chemistry; D013810:Therapeutic Equivalency; D014748:Vinca Alkaloids / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D014867:Water / Q000737:chemistry; D047392:beta-Cyclodextrins / Q000737:chemistry*
D003692:Delayed-Action Preparations; D013607:Tablets; D013644:Tartrates; D014748:Vinca Alkaloids; D047392:beta-Cyclodextrins; D014867:Water; C013983:vinpocetine; D008747:Methylcellulose